LOGOLOGOLOGOLOGO
    • About us
      • What we do
      • Who we are
        • Governance
        • Staff
        • Vacancies
    • Members
      • EuropaBio Members
      • About Membership
    • How we work
      • Healthcare Biotechnology Council
        • Patient BioForum
        • Study – Impact of the EU’s General Pharmaceutical Legislation
      • Industrial Biotechnology Council
        • EFIB
        • Microorganisms
      • National Associations Council
      • SME Platform
      • Biomanufacturing Platform
        • Biotechnology in our Lives
    • Activities
      • 25 Years of Innovation
      • The EU Biotech Act
      • European Biotech Week
      • EU Projects
        • PRIMED Project
        • APROVALS Project
    • News & Events
      • News
      • Events
    • Library
    Become a member
    ✕

    “Buying Innovative” in the Healthcare Biotech Market in Europe

    02/02/2017
    REPORT

    "Buying Innovative" in the Healthcare Biotech Market in Europe

    With regard to the healthcare biotechnology sector “buying innovative” means organising a public procurement process in a way that ensures a balance between the various public health objectives, i.e. securing access for patients to innovative therapies, guaranteeing high standards of quality, safety and efficacy of products purchased, and incentivising companies to compete in a free and dynamic internal market. More specifically in a way that:

    • Reflects patients’ needs and offers freedom of choice for doctors/patients, by ensuring that treatment options are not limited and decisions can always be made by a physician in consultation with patients. Given the recognised differences between biological medicines, a variety of biological medicines should be available for patients, not only a single medicine.
    • Respects physicians’ prescribing authority as regards decisions to keep treated patient with their current treatments or to alternate therapies. The decision to switch a patient to a new product should only be taken by the prescribing doctor in alignment with the patient and not be based on the results of a tendering process or purely on economic considerations.
    • Takes into account the complexity of biological medicines, including manufacturing practices, and for instance allows for sufficient lead times between an award decision and product delivery.
    • It is awarded based on careful consideration of additional criteria besides price, such as manufacturer experience, long-term efficacy and safety data, the need to ensure continuity of treatment, quality, services, manufacturing and reliability of supply as well as outcomes and additional potential costs (e.g. hospitalisations) incurred by patients and healthcare professionals during the course of previous therapeutic plans.
    • Fosters fair market competition and innovation, for instance by ensuring all manufacturers are able to compete with other bids and/or negotiate with payers on an equal footing.

    Download the full publication below.

    “Buying Innovative” in the Healthcare Biotech Market in Europe


    Download
    Share
    Communications Team
    Communications Team

    Related posts

    12/05/2026

    ‘Consistency, cooperation and practicality are the watch words’. EuropaBio reacts to provisional agreement on the Critical Medicines Act


    Read more
    23/04/2026

    ITRE’s recognition of the importance of biomanufacturing and of biotechnology as a horizontal enabling technology for Europe’s future in the European Competitiveness Fund


    Read more
    02/04/2026

    The EU Biotech Act II: A vital Act for biomanufacturing in Europe


    Read more

    Important links

    • Biodefence & Biosecurity in focus for EuropaBio with dedicated Task Force
    • ‘Consistency, cooperation and practicality are the watch words’. EuropaBio reacts to provisional agreement on the Critical Medicines Act

    Categories in our Newsroom

    EBIO-white

    EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

    Contact us

    Extra links

    Members
    Staff
    Privacy policy
    Legal & cookies
    Events
    Newsroom

    Become a member

    Media pack

    © 2026 Europabio. All Rights Reserved. Designed by EYAS
    Become a member

    Vitamin B2

    The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

    Insulin

    Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

    Detergents

    Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

    Clothes

    Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

    Algal Omega 3

    Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

    Cheese

    Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.